We present novel insight into the circulating microRNA profiles of pediatric patients with pulmonary hypertension. Our findings support the utility of microRNAs as both useful biomarkers of disease severity and potential therapeutic targets in pediatric pulmonary hypertension.
1 October 2025 in American Journal of Physiology-Heart and Circulatory Physiology
In this study, we utilize an ovine model of congenital heart disease-associated pulmonary arterial hypertension (CHD-PAH) to unveil the structural and transcriptional changes that underlie the maintenance of an adaptively hypertrophied right ventricle (RV). In CHD-PAH, the RV hypertrophies while maintaining microvascular density and expanding its cardiomyocyte population, structural and cellular adaptations that are critical to supporting RV function. These findings provide novel insight into myocardial growth mechanisms that are triggered by congenital pressure overload.
Pulmonary Arterial Hypertension (PAH) is a rare vascular disorder characterized by elevated pressure in pulmonary arteries, eventually leading to right ventricular failure. Approximately 50% of pediatric disease and 20% of adult disease can be linked to a genetic mutation, with nearly 70% of these cases involving mutations in the bone morphogenetic protein receptor type 2 ( BMPR2 ) locus. Investigations using rodent models have made significant advances in our understanding of BMPR2 signaling; however, limited data exist regarding the onset and course of PAH, and etiologies for phenotypic expression in these patients remain unknown. In this work, we describe the development of a novel ovine model of heritable PAH. Because homozygous disruption of BMPR2 is embryonic lethal, we developed heterozygous BMPR2 sheep by using a PAM-disrupting synonymous single stranded oligodeoxyribonucleotide alongside a single guide RNA and Cas9 mediated gene editing strategy. The resulting
BMPR2
(+/–) lambs demonstrated cardiac and pulmonary vascular pathology that are consistent with BMPR2 mutation-driven PAH observed in humans. Given the genetic and physiological similarities of
BMPR2
(+/–) sheep to humans with heritable PAH, this large animal model will serve as a vital platform for mechanistic molecular studies and will provide a much-needed pre-clinical model for extensive treatment evaluations.